Skip to main content

Catalyst Calendar

Tue, Aug 11, 2026

1 updates

4:05 PM

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

savarapharma.com

Thu, Jul 30, 2026

1 updates

8:05 AM

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

savarapharma.com

Fri, Jun 12, 2026

1 updates

4:05 PM

Savara Announces New Employment Inducement Grant

savarapharma.com

Mon, Jun 8, 2026

1 updates

4:05 PM

Savara Announces Chief Financial and Administrative Officer Transition

savarapharma.com

Wed, May 27, 2026

1 updates

4:05 PM

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

savarapharma.com

Wed, May 20, 2026

1 updates

8:15 AM

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Presentation / Abstract • Phase 3savarapharma.com

Tue, May 19, 2026

1 updates

2:15 PM

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

savarapharma.com

Mon, May 18, 2026

1 updates

2:55 PM

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

savarapharma.com